KLK3 and cancer: Along with chronic diseases, the problem of cancer, whose global diagnostics market will reach $168.6 billion by 2020 [21], is driving the development of innovative devices, focusing on the detection of protein biomarkers such as the prostate specific antigen (PSA), platelet factor 4, and carcinoembryonic antigen.